Merck & Co., Inc. (MRK) Stock Analysis — Probabli.AI
AI-powered analysis for MRK (Merck & Co., Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $140.93 · Market cap: $347.7B · AI outlook: Bullish
Merck & Co. (MRK) presents an attractive total return profile anchored by robust oncology cash flows, rapid uptake of newly launched growth drivers like Winrevair, and an advancing diversified pipeline. While the impending 2028 Keytruda loss of exclusivity represents the central strategic overhang, Merck is aggressively deploying capital into subcutaneous life-cycle management, next-generation…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $128 / P50: $158 / P90: $182
- Merck demonstrates resilient near-term earnings driven by continued Keytruda demand, rapid adoption of Winrevair (sotatercept), and raised fiscal guidance. Solid analyst consensus (BUY with median target of $165)…
5-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 5-year price estimates — P10: $135 / P50: $205 / P90: $270
SWOT Highlights
- Strength: Keytruda dominance as the world's top-selling oncology blockbuster generates massive free cash flow
- Strength: Fast-growing new launches like Winrevair (sotatercept) in pulmonary arterial hypertension offering multi-billion-dollar peak sales
- Risk: Extreme revenue concentration in Keytruda, creating significant vulnerability to patent expiration
- Risk: Elevated GAAP payout ratio driven by acquisition accounting and lumpy collaboration milestones
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
28 Wall Street analysts rate MRK a BUY with a mean price target of $160.14. Merck & Co., Inc. currently pays a dividend with a yield of approximately 2.41%.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
MRK forecast details · MRK sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Merck & Co., Inc. (MRK) — saved
Merck & Co. (MRK) presents an attractive total return profile anchored by robust oncology cash flows, rapid uptake of newly launched growth drivers like Winrevair, and an advancing diversified pipeline. While the impending 2028 Keytruda los
- Merck & Co., Inc. (MRK) — saved
Merck & Co., Inc. is well-positioned for growth with its robust pipeline, proven market leadership, and strategic initiatives, despite facing challenges such as competition and legal disputes. Investors should consider the stock a bullish l
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.